Ignite Creation Date:
2024-07-17 @ 10:47 AM
Last Modification Date:
2024-10-26 @ 3:34 PM
Study NCT ID:
NCT06501534
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-07-15
First Post:
2024-07-02
Brief Title:
A Dose Finding Study to Assess Efficacy and Safety of IBI128 in Chinese Gout Subjects
Sponsor:
Innovent Biologics Suzhou Co Ltd
Organization:
Innovent Biologics Suzhou Co Ltd
Study Overview
Official Title:
A Randomized Open Label Multicenter Parallel-group Positive-controlled Dose Finding and Phase II Study to Assess Efficacy and Safety of IBI128 in Chinese Gout Subjects
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
IBI128 Tigulixostat is a novel non-purine selective inhibitor of xanthine oxidase XO The XO inhibitors lower uric acid concentrations in serum by inhibiting the production of uric acid
This ia a randomized open label multicenter parallel-group positive-controlled dose finding and Phase II study to assess efficacy and safety of IBI128 in chinese gout subjects
This ia a randomized open label multicenter parallel-group positive-controlled dose finding and Phase II study to assess efficacy and safety of IBI128 in chinese gout subjects
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None